首页> 外文期刊>Applied cancer research. >Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?
【24h】

Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?

机译:在前肢妇科癌症群体中所选高级恶性肿瘤的突变分析:有针对性疗法的潜力吗?

获取原文
           

摘要

In 2017, there will be 107,000 cases of gynecologic cancer diagnosed in the US with an overall survival of around 70%-most occurring in post-menopausal individuals. In this study, we have examined a younger (≤?40?years of age) subpopulation of these women with high grade/ high stage gynecologic malignancies, attempting to identify unique genetic abnormalities or combinations thereof through tissue block specimens. This information was then analyzed in light of known target therapies to see if genetic analysis in this setting would yield significant therapeutic advantage. We retrospectively evaluated patients with high grade/high stage gynecologic cancers (≤?40?years of age), examined the presence and status of 400 oncogenes and tumors suppressor genes from Formalin-fixed, Paraffin-embedded (FFPE) tissue and functionally classified mutations by SIFT and Polyphen. Twenty women were identified and stratified into positive and negative outcomes. No demographic, clinicopathologic or treatment factors were significant between these groups. Of the 400 genes evaluated, twelve mutations were significant between the groups, six with targeted therapies. Mutations associated with negative outcomes within histologies/locations were evaluated: ERBB3 in epithelial (ovarian), ALK/GPR124/KMT2D in neuroendocrine (ovarian/endometrial), ROS1/EGFR, ROS1/ERBB3/KMT2D/NIRK1 and GPR124 in sarcoma. All negative outcomes were void of mutations in APC/ABL2. A predictive model for negative outcomes in our cohort was developed from these data: AKAP9-/MBD1-/APC-/ABL2- with a mutation load of ?20.5. Unique multi-gene and mutational outcome correlations were identified in our cohort. Resulting complex mutational profiles in distinctly aggressive gynecologic cancers suggested potential for novel therapeutic treatment. Future larger scale studies will be needed to correlate the genotypic and phenotypic features identified here.
机译:在2017年,将有107,000例妇科癌症患者诊断,整体存活率约为70% - 绝经后的人。在这项研究中,我们研究了一个更年轻(≤10岁)的这些妇女患有高品位/高阶妇科恶性肿瘤的亚群,试图通过组织块标本确定独特的遗传异常或其组合。然后根据已知的靶疗法分析该信息,看看该设置中的遗传分析是否会产生显着的治疗优势。我们回顾性地评估了高品位/高阶妇科癌症的患者(≤40岁),检查了来自福尔马林固定的石蜡嵌入(FFPE)组织和功能分类突变的400个癌基因和肿瘤抑制基因的存在和状态通过筛选和复合。鉴定了20名女性并分层成正面和消极结果。这些组之间没有人口统计学,临床病理学或治疗因子是显着的。在评估的400个基因中,在组之间的12个突变中是显着的,六个具有靶向疗法。评估与组织学/地区内的阴性结果相关的突变:在神经内分泌(卵巢/子宫内膜),ROS1 / EGFR,ROS1 / ERBB3 / KMT2D / NIRK1和肉瘤中的rOS1 / EGFR,ROS1 / ERBB3 / KMT2D / NIRK1和GPR124中的ERBB3。所有负面结果均为APC / Abl2中的突变。从这些数据开发了我们的队列中的负面结果的预测模型:akap9- / mbd1- / apc- / abl2-具有>?20.5的突变负荷。在我们的队列中确定了独特的多基因和突变结果相关性。产生复杂的突变型材,以明显侵略性的妇科癌症表明新的治疗治疗潜力。将来需要更大的规模研究来关联此处鉴定的基因型和表型特征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号